title: Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib.
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ohyashiki
authors.forename: Sei-ichiro
authors.initials: S
authors.lastname: Katagiri
authors.forename: Tetsuzo
authors.initials: T
authors.lastname: Tauchi
authors.forename: Junko H
authors.initials: JH
authors.lastname: Ohyashiki
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Maeda
authors.forename: Itaru
authors.initials: I
authors.lastname: Matsumura
authors.forename: Tai-ichi
authors.initials: T
authors.lastname: Kyo
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D017252:CD3 Complex / Q000097:blood / Q000276:immunology*; D016827:CD8 Antigens / Q000097:blood / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D019041:L-Selectin / Q000097:blood / Q000276:immunology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D018655:Lymphocyte Count; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D017252:CD3 Complex; D016827:CD8 Antigens; D010879:Piperazines; D011743:Pyrimidines; D019041:L-Selectin; D000068877:Imatinib Mesylate